Malignant peripheral nerve sheath tumour (MPNST)

What changed: Malignant peripheral nerve sheath tumour (MPNST)

Cancer page →

Every dated change on the records linked to Malignant peripheral nerve sheath tumour (MPNST), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result1Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMalignant peripheral nerve sheath tumour (MPNST)
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025MilestoneMirdametinib
Mirdametinib approved for NF1 plexiform neurofibromas in adults and children
A milestone in how this cancer is treated.

2020 · 1

2020MilestoneSelumetinib
Selumetinib approved for NF1 plexiform neurofibromas, the precursor lesion
A milestone in how this cancer is treated.

2017 · 1

2017MilestoneDoxorubicin
SARC006: neoadjuvant chemotherapy responses in a minority, fewer in NF1-associated tumours
A milestone in how this cancer is treated.

2016 · 1

2016MilestoneMalignant peripheral nerve sheath tumour (MPNST)
H3K27me3 loss adopted as a diagnostic marker
A milestone in how this cancer is treated.

2014 · 2

1990 · 1

1990MilestoneMalignant peripheral nerve sheath tumour (MPNST)
NF1 gene cloned
A milestone in how this cancer is treated.